Morgan Stanley raised the firm’s price target on McKesson (MCK) to $966 from $916 and keeps an Overweight rating on the shares. The “Golden Era” of healthcare distribution continues, argues the analyst, who still sees scope for group multiple expansion in a “robust backdrop” and also cites the relative policy insulation of the group.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- Synergy CHC expands FOCUSfactor functional across Canada
- McKesson: Expanding Biosimilar and Oncology Platform Drives Incremental Upside and Supports Buy Rating
- Wells says ‘Great Healthcare Plan’ lacks new onerous proposals
- McKesson price target raised to $968 from $928 at Baird
- 3 Best ETFs to Invest In, According to AI Analyst, 12/15/2025